BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Holbrook MC, Goad DW, Grdzelishvili VZ. Expanding the Spectrum of Pancreatic Cancers Responsive to Vesicular Stomatitis Virus-Based Oncolytic Virotherapy: Challenges and Solutions. Cancers (Basel) 2021;13:1171. [PMID: 33803211 DOI: 10.3390/cancers13051171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Goad DW, Bressy C, Holbrook MC, Grdzelishvili VZ. Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. Mol Ther Oncolytics 2022;24:59-76. [PMID: 34977342 DOI: 10.1016/j.omto.2021.11.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Marchini A, Ilkow CS, Melcher A. Oncolytic Virus Immunotherapy. Cancers (Basel) 2021;13:3672. [PMID: 34359574 DOI: 10.3390/cancers13153672] [Reference Citation Analysis]
3 Nisar M, Paracha RZ, Adil S, Qureshi SN, Janjua HA. An Extensive Review on Preclinical and Clinical Trials of Oncolytic Viruses Therapy for Pancreatic Cancer. Front Oncol 2022;12:875188. [PMID: 35686109 DOI: 10.3389/fonc.2022.875188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG. Trial watch: intratumoral immunotherapy. Oncoimmunology 2021;10:1984677. [PMID: 34676147 DOI: 10.1080/2162402X.2021.1984677] [Reference Citation Analysis]